Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients

Date

12 Dec 2024

Session

Poster Display session

Presenters

Anita Semertzidou

Citation

Annals of Oncology (2024) 24 (suppl_1): 1-16. 10.1016/iotech/iotech100742

Authors

A. Semertzidou1, S. Hassanieh2, E.M. Wigmore3, O. Arqués4, Z. Lai5, A.E. Storti6, M. Heininen-Brown6, S. Willis7, B. Nuttall8, M. Scaltriti9, R. Stewart10, E. De Bruin11, H. Angell12

Author affiliations

  • 1 Imperial College London - Hammersmith Campus, London/GB
  • 2 AstraZeneca PLC, CB2 0AA - Cambridge/GB
  • 3 Astra Zeneca, Cambridge/GB
  • 4 AstraZeneca Farmaceutica Spain S A, Madrid/ES
  • 5 AstraZeneca, Waltham/US
  • 6 AstraZeneca Computational Pathology GmbH, Munich/DE
  • 7 AstraZeneca UK Ltd, Cambridge/GB
  • 8 AstraZeneca, South San Francisco/US
  • 9 AstraZeneca - NY, New York/US
  • 10 AstraZeneca, Northolt/GB
  • 11 AstraZeneca UK, Cambridge/GB
  • 12 AstraZeneca, Cambridge/GB

Resources

This content is available to ESMO members and event participants.

Abstract 47P

Background

Compared with other breast cancer subtypes, TNBC is characterised by higher tumour mutational burden, elevated levels of PD-L1 expression and increased levels of immune cell infiltration. Predictors of immunotherapy response are not yet fully elucidated with several responders harbouring both PD-L1- and TMB-low tumours. We investigated the clinical and molecular traits associated with PD-L1 expression in TNBC patients with the aim to uncover distinct signatures that may impact on PD-L1 status and could potentially explain divergent responses to ICIs.

Methods

We performed WES, RNAseq and IHC using FFPE blocks from primary tumour resections derived from 196 treatment-naïve TNBC patients. Slides were stained with the anti- PD-L1 clone 22C3 and scored using a cut-off of CPS>=10 for PD-L1-high samples. DGE analysis was conducted between PD-L1-high and -low cases. The read count matrix was normalized using the median of ratios via DESeq2. A generalized linear model identified DEGs, followed by pathway analysis using over-representation analysis with KEGG pathways. Additionally, GSEA was employed to evaluate specific gene sets within the expression data.

Results

Almost one fourth of TNBC patients were PD-L1-high. The most frequent mutations in both groups involved TP53, PIK3CA, BRCA1, RB1 and PTEN genes with PIK3CA mutations almost exclusively encountered in PD-L1-high tumours. In PD-L1-high tumours, most DEGs (n=1708) were downregulated, including cell adhesion and collagen-related genes, while the up-regulated genes (n=481) included HLA isotypes, IFN-gamma, JAK2 and STAT1. Most DEGs were involved in the neuroactive ligand-receptor interactions, calcium, cAMP and cell adhesion signalling pathways. Immune, chemokine and JAK-STAT signalling pathways were positively enriched in PD-L1-high tumours.

Conclusions

This integrative analysis of clinical, genetic, transcriptomic and immunohistochemical data revealed differences in mutational signatures and gene expression patterns between PD-L1-high and -low TNBC tumours.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

A. Semertzidou, O. Arqués, Z. Lai: A.E. Storti, M. Heininen-Brown, S. Willis, B. Nuttall, M. Scaltriti, R. Stewart: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca. S. Hassanieh, E.M. Wigmore: Financial Interests, Institutional, Full or part-time Employment, Shareholder: AstraZeneca. E. De Bruin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. H. Angell: Financial Interests, Institutional, Advisory Board: AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.